BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23257430)

  • 1. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Wang L; Jiang H; Li H; Shao JB; Lu ZH; Yang JW; Yang WQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):400-3. PubMed ID: 21781499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
    Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
    Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
    J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation on protocol SCMS-ALL-2005 for childhood B lineage acute lymphoblastic leukemia].
    Tang JY; Xue HL; Chen J; Pan C; Li BS; Gu LJ; Dong L; Hu WT; Shen SH; Zhou M; Ye QD; Jiang H; Luo CY
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):546-50. PubMed ID: 22490159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
    Eveillard M; Robillard N; Arnoux I; Garand R; Rialland F; Thomas C; Strullu M; Michel G; Béné MC; Fossat C; Loosveld M
    Hematol Oncol; 2017 Jun; 35(2):237-243. PubMed ID: 26449287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of clinical features and prognostic significance of childhood T-lineage acute lymphoblastic leukemia].
    Zhang YL; Zhao WL; Nie SS; Guo DD; Ji ZH; Chai YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1496-500. PubMed ID: 22169311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.
    Xu XJ; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2012 Aug; 36(8):1022-7. PubMed ID: 22483330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
    Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
    Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
    Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Chen J; Jiang LM; Dong L; Pan C; Ye H; Song DL; Xue HL; Tang JY; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):120-3. PubMed ID: 16732969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.